title: Does the concept of lower-risk myelodysplastic syndrome need to be revisited?
authors.affiliation: Hospital Universitario Virgen del Rocío, Sevilla, Spain; Instituto de BioMedicina de Sevilla (IBIS), CSIC, Universidad de Sevilla, Spain. Electronic address: josef.falantes.sspa@juntadeandalucia.es.
authors.forename: Jose F
authors.initials: JF
authors.lastname: Falantes
authors.affiliation: Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
authors.forename: Guillermo
authors.initials: G
authors.lastname: Garcia-Manero
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D006801:Humans; D009190:Myelodysplastic Syndromes / Q000188:drug therapy / Q000401:mortality*; D011379:Prognosis; D012306:Risk
chemical_list: D000970:Antineoplastic Agents